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ABSTRACT Chiral column liquid chromatography and enantiospecific enzymatic
hydrolysis were utilized to separate the enantiomers of a- and b-dihydrotetrabenazine
and a-9-O-desmethyldihydrotetrabenazine, three benzo[a]quinolizines derived from the
amine-depleting drug tetrabenazine. An X-ray crystal structure analysis of (−)-a-9-O-
desmethyldihydrotetrabenazine gave an absolute structure of that compound as the 2S,
3S, 11bS isomer. Therefore, (−)-a-dihydrotetrabenazine also has the 2S, 3S, 11bS abso-
lute configuration. (+)-a-Dihydrotetrabenazine, the single biologically active isomer from
the metabolic reduction of tetrabenazine, thus has the absolute configuration of 2R, 3R,
11bR. For further in vitro and in vivo studies of the vesicular monoamine transporter, it
is now possible to use the single enantiomer of radiolabeled a-dihydrotetrabenazine.
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INTRODUCTION
Tetrabenazine, used clinically for the management of
movement disorders, functions to deplete brain mono-
amine levels by inhibition of the vesicular monoamine
transporter type 2 (VMAT2).1 In rodents and humans, tet-
rabenazine is rapidly and extensively metabolized by re-
duction of the 2-keto group, producing a- and b-dihydro-
tetrabenazine2 (Fig. 1). These alcohols also have high in
vitro affinity for the VMAT2, and are likely the pharmaco-
logically active agents in the mammalian brain.3 a-Dihy-
drotetrabenazine and related benzo[a]quinolizines have re-
cently been labeled with tritium and carbon-11 radioiso-
topes and used for in vitro and in vivo studies of the
VMAT2 in animal and human brain.4,5
As part of our study of the structure-activity relationship
for the binding of benzo[a]quinolizines to the VMAT26 we
determined the relative configurations of a- and b-dihydro-
tetrabenazines, demonstrating that these compounds (and,
indirectly, tetrabenazine) were racemic mixtures of two
enantiomers. After completing resolution of the enantio-
mers on a chiral HPLC column, we then reported that the
in vitro binding of a-dihydrotetrabenazine was stereospe-
cific, with a high binding affinity (Ki = 0.97 nM) only for the
(+)-isomer.7 At that time, we were unable to determine the
absolute configuration, and thus report here syntheses,
resolution and X-ray crystallographic studies which allow
the assignment of the absolute configuration of (+)-a-
dihydrotetrabenazine.
MATERIALS AND METHODS
Chemicals were purchased from Aldrich Chemical Co.
and are reagent grade unless otherwise noted. Procine pan-
creatic lipase (Altus 3) and ChiroCLEC™-PC dry (Altus 20)
were purchased from Altus Biologic Inc. (Boston, MA).
Silica gel for column chromatography (70–230 mesh
ASTM) and silica gel thin layer chromatography plates
were purchased from Merck Co. (±)-a-Dihydrotetrabena-
zine was prepared by hydride reduction of tetrabenazine
(Fluka Chem. Co.) as previously described.6 Melting
points were determined on a Mel-Temp apparatus and are
uncorrected. Optical rotations were obtained using a Per-




a-Dihydrotrabenazine was selectively demethylated at
the 9-methoxy group using sodium hydride/N-methyl ani-
line/HMPA12. N-Methylaniline (7.89 g, 74 mmol) was
added dropwise at 65°C to a stirred suspension of sodium
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hydride (2.677 g; 111 mmol) in dry xylene (20 ml) and
hexamethylphosphoramide (13.20 g; 74 mmol). After 15
min (±)-a-dihydrotetrabenazine (11.900 g, 37.3 mmol) sus-
pended in 10 ml xylene was added dropwise with stirring.
The suspension was stirred 48 h at 65°C. The reaction
mixture was hydrolyzed with 5% HCl (50 ml) and extracted
several times with ether to remove unreacted starting ma-
terial. The aqueous phase was filtered through a glass frit,
and to the clear brown solution was added HCl (conc.)
dropwise to precipitate the product. The solid was then
dissolved in methanol/NH4OH to obtain the free base of
the crude product. The resulting solid was recovered by
filtration and recrystallized several times from small vol-
umes of methanol. Yield of (±)-a-9-O-desmethyldihydrotet-
rabenazine was 3.444 g (30%). The product was @98% pure
as determined by HPLC (Inertsil C8; UV 240 nm; 1:5.5
CH3CN:10 mM ammonium acetate, pH 4.5; Rt 12 min) and
was identical by HPLC and 1H-NMR to a sample of (±)-9-
desmethyl-a-dihydrotetrabenazine synthesized stepwise
from 3-benzyloxy-4-methoxybenzaldehyde.2 m.p. 187–190°
(lit.2 192.5–193°). 1H nmr (d ppm, CD3OD): 6.84 (1H,s,H-
8), 6.67 (1H,s,H-11), 4.43 (1H,d,12Hz,H-11b), 3.87
(3H,s,CH3-10), 3.71 (1H,m,H-6), 3.63 (2H,m,H-4, 2), 3.33
(1H,m,H-7), 3.26 (1H,m,H-6), 3.00 (2H,m,H-4, 7), 2.89
(1H,m,H-1), 1.99 (1H,m,H-3), 1.77 (3H,m,H-1, 18, 28), 1.15
(1H,ddd, 16Hz,8Hz,8Hz,H-18), 1.00 (3H,d,7.5Hz, CH3-38),
0.97 (3H,d,7.5Hz, CH3-38). 13C nmr (d ppm, CD3OD): 148.4
(C-9), 147.7 (C-10), 125.2 (C-11a), 124.5 (C-7a), 116.1 (C-8),
109.4 (C-11), 72.0 (C-2), 62.6 (C-11b), 58.6 (C-4), 56.6
(OCH3), 51.9 (C-6), 40.4 (C-3), 39.9 (C-1), 39.2 (C-18), 27.1
(C-7), 26.2 (C-28), 24.9 (C-38), 21.9 (C-38). Anal. (HRMS)
Calcd. 305.1991; Found 305.1977. Specific rotation [a] = 0.





High performance liquid chromatography (HPLC) reso-
lutions of the isomers of (±)-a-dihydrotetrabenazine, (±)-b-
dihydrotetrabenazine, and (±)-9-O-desmethyl-a-dihydro-
tetrabenazine were done using a preparative HPLC column
[Chirex 3014: ((S)-val—(R)-1-(a-naphthyl)ethylamine), 20
× 250 mm: Phenomenex], eluted with 60:30:9.5:0.5 hexane:
1,2-dichloroethane:ethanol:trifluoroacetic acid at a flow
rate of 7 ml/min. Isolated products were re-injected until
pure by analytical HPLC analysis, determined using an ana-
lytical (4.6 × 250 mm) Chirex 3014 column and the above
solvent mixture at a flow rate of 1 ml/min. To obtain the
best separation each injection contained no more than 30
mg, and fractions were pooled to obtain sufficient quanti-
ties (>300 mg) of both the (−)- and (+)-isomers for further
chemical or biological characterization.
For resolution of (±)-a-9-O-desmethyldihydrotetrabena-
zine, the first enantiomer eluting was the (−)-isomer, @99%
pure, molecular rotation Mlt = −152.7. This material was
recrystallized from ethanol, and was used to grow the crys-
tals which were suitable for X-ray structure determination
(see following section). The (+)-isomer eluted second, and
was obtained in @98% enantiomeric purity.
For separation of the (±)-a-dihydrotetrabenazine, the en-
antiomers eluted in the same order as for a-9-O-
desmethyldihydrotetrabenazine. The molecular rotation
for the (+)-isomer was Mlt = 84.6.
Finally, the HPLC column was used for the resolution of
the enantiomers of (±)-b-dihydrotetrabenazine, where the
(+)-isomer eluted first: the molecular rotation for the (−)-
isomer was Mlt = −174.5.
Synthesis of (±)-a-Dihydrotetrabenazine Acetate Ester
(2-Acetoxy-3-Isobutyl-9,10-Dimethoxy-1,2,3,4,6,7-
Hexahydro-11bH-Benzo[a]quinolizine)
A solution of (±)-a-dihydrotetrabenazine (1 g, 3.13
mmol) in acetic anhydride (20 ml) was heated to reflux for
5 h. The solvent was then removed by a stream of N2 to
provide a dark oily residue. The oil was then purified by
silica gel column chromatography (EtOAc) to provide
crude ester, which was crystallized from EtOAc. The reac-
tion yield was almost quantitative. HRMS: calcd 361.2253;
found 361.2255. The product was used for the enzymatic
resolution (below) without further purification.
Enzymatic Resolution of (+)-a-Dihydrotetrabenazine
The Altus [3 (26.684 g) was poured into 750 ml of so-
dium phosphate buffer solution (0.12 M, pH = 7) and
stirred at room temperature for 20 min. The substrate ester
((±)-a-dihydrotetrabenazine acetate, 738 mg, 2.043 mmol)
dissolved in acetone (85 ml) was then slowly added. The
reaction mixture was stirred at room temperature for one
hour, then transferred to cold room (4°C) for 17 d. The
enzyme was then filtered out (celite). The clear aqueous
solution was adjusted to pH = 8 and extracted with CH2Cl2
(3 × 150 ml). The combined organic extracts were concen-
trated and separated by silica gel column chromatography
(EtOAc eluent) to provide (−)-ester (250 mg, containing a
small amount of the (+)-ester) and (+)-a-dihydro-
tetrabenazine (143 mg, 0.448 mmol) which was @99% pure
by analytical chiral HPLC analysis.
X-Ray Crystal Structure Analysis
A sample of crystalline (−)-a-9-O-desmethyldihydrotetra-
benazine (C18H28O3N + CF3CO2-CH3CH2OH) was
mounted in a thin-walled capillary to preserve the lattice
solvent. Crystallographic data was collected at room tem-
perature on a S/N/S automated R3 diffractometer with
monochromated Mo radiation. Absorption corrections
were applied in the basis of psi scans. The structure was
solved using the programs of SHELXL-93.8 To determine
Fig. 1. Structures of tetrabenazine and dihydrotetrabenazine. For sim-
plicity, a single enantiomer of each (3R, 11bR-tetrabenazine and 2R, 3R,
11bR-dihydrotetrabenazine) are shown.
60 KILBOURN ET AL.
absolute configuration, the entire sphere of hkl data was
collected and compared. In SHELXL-93, the absolute con-
figuration parameter is near zero when the configuration
assignment is correct, and near +1 when the configuration
is wrong. For this data set, the absolute structure param-
eter refined to −0.4 ± 0.3 for the assignment shown in Fig-
ure 2. When the opposite configuration was tested, the
parameter was +1.3 ± 0.3.
Crystal data are presented in Table 1, and the final
atomic coordinates are given in Table 2. The molecular
geometry and crystallographic labeling are shown in Fig-
ure 2.
RESULTS AND DISCUSSION
Starting from commercially available tetrabenazine, it is
possible to synthesize a large number of derivatives
through reduction, demethylation, and organometallic ad-
dition reactions.1,6 Cleavage of the methoxy groups of such
compounds, either using the basic conditions reported
here or using acidic conditions such as boron trihalides,9
are low to moderate yield reactions requiring separation of
the desired product from numerous impurities. Assign-
ment of the isolated product as the 9-O-desmethyldihydro-
tetrabenazine, rather than the 10-O-desmethyl compound,
was done on the basis of an X-ray crystal structure of the
racemic mixture (data not shown), and verified by com-
parison with a sample of authentic 9-O-desmethyldihydro-
tetrabenazine synthesized from 3-benzyloxy-4 -
methoxybenzaldehyde.2 Demethylation of tetrabenazine
using boron tribromide yields primarily the 10-desmethyl
isomer as determined by NMR and X-ray crystallographic
analysis (data not shown), rather than the 9-desmethyl iso-
mer as originally reported.9 Although a moderate yield re-
action, the one-step demethylation of a-dihydrotetrabena-
zine using the sodium hydride/N-methylaniline/HMPA
method was considerably easier than the multi-step total
synthesis.
Through the use of 2-D NMR techniques it has been
determined that all of these compounds, and tetrabenazine
itself, are a mixture of enantiomers with the identical rela-
tionship of configurations at C-3 and C-11b.6,10 The biologi-
cal activity of a-dihydrotetrabenazine resides in the (+)-
isomer (Ki = 0.97 nM), with a very low affinity in vitro for
the other enantiomer (2200 nM).7 Two methods were de-
veloped for the resolution of enantiomers of these benzo[a-
]quinolizines. Application of chiral column HPLC provides,
using repetitive injections, a suitable method for resolution
and purification of sufficient amounts of resolved isomer
for further use: the resolved (+)-a-9-O-desmethyldihydro-
tetrabenazine, for example, serves as the precursor for the
synthesis of (+)-a-[11C]dihydrotetrabenazine (via alkyla-
tion with [11C]methyl iodide) which is used in imaging of
human brain monoamine vesicular transporters using pos-
itron emission tomography.11 As an alternative method of
synthesis of the resolved isomer, we also examined the
enantiospecific hydrolysis of an acetate ester of (±)-a-
dihydrotetrabenazine using porcine pancreatic lipase (Al-
tus 3). This enzyme selectively deacetylated the (+)-ester
to provide a mixture of (+)-a-dihydrotetrabenazine and un-
hydrolyzed ester (enriched in the (−)-isomer). After sepa-
ration of alcohol and ester on a silica gel column, pure
(+)-a-dihydrotetrabenazine could be obtained. Although
this was a suitable method for also obtaining useful quan-
tities of pure resolved isomer, attempts to scale the enzyme
synthesis 10-fold were less successful.
Of the pure resolved compounds which were prepared,
Fig. 2. Diagram of (−)-a-9-O-desmethyldihydrotetrabenazine with thermal ellipsoids representing 50% probability. The absolute configurations at
atoms C9, C11, and C12 (corresponding to the 11b, 2, and 3-positions of the tetrabenazine structure shown in Fig. 1) are all S.




Formula C22H34F3NO6 Formula weight 465.50 amu
a 9.438(2) Å space group monoclinic P21
b 12.953(3) Å T 22°C
c 10.070(2) Å l 1.54178 Å
b 92.40(2) ° Goodness of fit 1.039
V 1230.0(5) Å3 r(calc) 1.257 g cm−3
Z 2 µ 8.93 cm−1
transmission coefficients 0.940–0.592
R 0.045 for I > 2s(I); 0.049 for all 2486 data
wR 0.120 for I > 2s(I); 0.123 for all 2486 data
refinement method: full-matrix least-squares on F2
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we were successful at growing good crystals from the (−)-
a-9-O-desmethyldihydrotetrabenazine, and thus the deter-
mination of absolute configuration was done on that com-
pound. The crystal structure determined is shown in Fig-
ure 2, and can be assigned as the 2S, 3S, 11bS isomer. As
(−)-a-9-O-desmethyldihydrotetrabenazine can be con-
verted to the corresponding (−)-a-dihydrotetrabenazine by
simple O-methylation of the phenol group, the absolute
configuration of (−)-a-dihydrotetrabenazine (the inactive
isomer) is also 2S, 3S, 11bS, and thus the configuration of
the high affinity (+)-a-dihydrotetrabenazine is 2R, 3R, 11bR
(as depicted in Fig. 1). The resolution of the desmethyl
compound, a-9-O-desmethyldihydrotetrabenazine, has also
allowed us to prepare the single active enantiomer (+)-2R,
3R, 11bR-dihydrotetrabenazine in both tritium and carbon-
11 labeled forms,7 providing the optimal radioligands for in
vitro and in vivo studies of the vesicular monoamine trans-
porter type 2.
Finally, as a-dihydrotetrabenazine is obtained from tet-
rabenazine by a simple hydride reaction which produces
the chiral center at C-2 but does not racemize the carbon
centers at C-3 and C-11b, these studies would suggest that
tetrabenazine itself may consist of active (3R, 11bR) and
inactive (3S, 11bS) enantiomers. The relative biological ac-
tivities of the enantiomers of tetrabenazine do, however,
remain to be verified.
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TABLE 2. Atomic coordinates (×10ˆ4) and equivalent
isotropic displacement parameters (Aˆ2 × 10ˆ3)a
x y z U (eq)
C (1) 122 (5) 1435 (3) 8178 (4) 49 (1)
C (2) −940 (4) 1764 (3) 8932 (4) 49 (1)
O (1) −2234 (3) 1313 (2) 8819 (3) 60 (1)
C (3) −667 (4) 2588 (3) 9805 (4) 45 (1)
O (2) −1801 (3) 2844 (2) 10555 (3) 62 (1)
C (4) 636 (4) 3051 (3) 9857 (4) 48 (1)
C (5) 1709 (4) 2723 (3) 9052 (3) 42 (1)
C (6) 1468 (4) 1886 (3) 8226 (3) 43 (1)
C (7) 2618 (5) 1490 (4) 7365 (4) 55 (1)
C (8) 4067 (5) 1854 (3) 7817 (5) 54 (1)
N (1) 4008 (3) 3003 (2) 7992 (3) 40 (1)
C (9) 3112 (4) 3298 (3) 9139 (4) 45 (1)
C (10) 2971 (4) 4461 (3) 9133 (4) 50 (1)
C (11) 4398 (4) 5007 (3) 9241 (4) 45 (1)
O (3) 4213 (3) 6097 (2) 9252 (3) 52 (1)
C (12) 5363 (4) 4658 (3) 8151 (4) 46 (1)
C (13) 5417 (5) 3477 (3) 8145 (6) 50 (1)
C (14) 6837 (5) 5140 (4) 8309 (6) 62 (1)
C (15) 7918 (5) 4861 (4) 7321 (5) 74 (1)
C (16) 9322 (7) 5390 (7) 7700 (9) 114 (2)
C (17) 7371 (8) 5086 (7) 5890 (6) 108 (2)
C (18) −1586 (7) 3619 (4) 11551 (6) 71 (1)
O (4) 4545 (5) 2861 (4) 4869 (3) 105 (1)
O (5) 2845 (4) 3767 (2) 5673 (3) 73 (1)
C (19) 3561 (6) 3455 (3) 4771 (4) 63 (1)
C (20) 3157 (10) 3828 (6) 3387 (6) 112 (2)
F (1) 3293 (11) 3173 (6) 2497 (4) 264 (5)
F (2) 1984 (6) 4274 (5) 3212 (5) 178 (2)
F (3) 4032 (9) 4557 (7) 3070 (7) 253 (4)
O (6) 6317 (5) 1868 (3) 3215 (4) 93 (1)
C (21) 7318 (11) 1477 (7) 4081 (11) 171 (4)
C (22) 8077 (10) 2111 (8) 4932 (8) 147 (3)
aU(eq) is defined as one-third of the trace of the orthogonalized Uij tensor.
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